To utilize historical patient records to identify “non strictly IPF” patients with progressive lung fibrosis who may benefit from pharmacological management with approved IPF therapies by characterizing and comparing (i) clinical presentation (over time); (ii) characteristics (clinical and demographic) at time of diagnosis and (iii) clinical progression of patients diagnosed with IPF and those with “non strictly IPF” progressive fibrotic lung conditions.
Alison Chisholm, UK
Anjan Nibber, UK
Status: Proposed Study, Seeking Funding
Documents and Publications: